Su_niary A pilot study of continuous infusional 5-fluorouracil 200 mg m' per 24 h by ambulatory pump and Hickman line for the entire treatment cycle with mitomycin C 8 mg m-i.v. on day I and cisplatin 75 mg m' i.v. on day 1, both repeated every 28 days, was carried out in 31 previously untreated patients with advanced non-small-cell lung cancer (NSCLC). Of 31 patients assessable for response, one attained a complete remission and eight a partial remission, an overall response rate of 29%. Haematological toxicity was minimal, with only 3% of patients developing WHO grade III IV neutropenia and 13% grade III LV thrombocytopenia. Significant side-effects included moderate to severe emesis (41%), mucositis (34%), diarrhoea (31°%) and palmar-plantar syndrome (14%). Seven patients (23%) had Hickman line complications requiring line removal. Continuous infusional chemotherapy with this regimen is active in advanced non-small-cell lung cancer, but its complexicity and associated treatment toxicity offer little advantage over equally active but simpler and less toxic cisplatin-based regimens.
Combination chemotherapy is increasingly being accepted as having a role in the management of advanced non-small-cell lung cancer (NSCLC) . A number of recent trials have shown a survival benefit for combination chemotherapy over best supportive care (Cormier et al., 1982; Rapp et al., 1988; Cartei et al., 1993) and a recent overview analysis confirmed a significant, although modest, survival benefit in favour of chemotherapy (Souquet et al., 1993) . No one regimen has been shown to be superior to others in terms of survival in the treatment of advanced NSCLC, although cisplatin-based regimens appear to offer the best response rates (Veronesi et al., 1988; Luedke et al., 1990) . Common regimens in use include cisplatin/etoposide (Ruckdeschel et al., 1986) , MVP (mitomycin, vinblastine, cisplatin) (Ruckdeschel et al., 1986) and MIC (mitomycin, ifosfamide, cisplatin) (Cullen et al., 1988) . In our own institution we have developed a moderatedose MVP regimen that appears to be effective, cheap and very well tolerated (Hardy et al., 1989) .
Infusional 5-fluorouracil (5-FU) has been shown to be more effective than bolus injection in colon cancer (Lokich et al., 1989) and has resulted in very high response rates when used in conjunction with epirubicin and cisplatin (ECF) in the treatment of advanced gastric cancer (Findlay et al., 1994) and carcinoma of the breast (Smith et al., 1993) . In order to try and improve on the above results in advanced NSCLC, we undertook a pilot phase II study of continuous infusion 5-FU (in the same dose as had been shown to be effective in the above studies) in conjunction with cisplatin and mitomycin C (another agent with known single-agent activity in NSCLC). The aim of the study was to determine response rate, feasibility of administration, toxcicity and effect on survival of this regimen. Seven of nine patients (78%) with an objective response to treatment gained symptomatic relief. However, 14 of 21 patients (67%) with no change or progressive disease on objective response assessment also gained symptomatic relief. Toxicityi This regimen had a low incidence of bone marrow toxicity, with only one patient developing WHO grade I1IiIV neutropenia and four developing WHO grade III/IV thrombocytopenia. Two patients developed significant neutropemnc infection, but there were no toxic neutropenic deaths. The most significant non-haematological toxicity was emesis, with 12 patients (41%) developing grade III/IV nausea or vomiting. Although seldom severe, diarrhoea, mucositis, and palmar-plantar erythema were experienced by 31%, 34% and 14% of patients respectively. Only two patients developed significant alopecia, and there were few other significant side-effects. A detailed outline of the toxicity profile is given in Table IV .
Dose reductions
Eight patients (26%) required a 25% dose reduction of at least one drug. In two cases cisplatin dose was reduced due to a reduction in EDTA clearance below 60 ml min-'. In three patients 5-FU was reduced because of palmar-plantar erythema, and in three patients because of grade III thrombocytopenia. No patient required cessation of treatment because of treatment-induced toxicity.
Hickman line complications Seven patients (23%) experienced significant Hickman line complications, in six of whom the line required removal. Two patients developed grade III line infections and three patients developed subclavian venous thrombosis requiring line removal, one of whom also developed a pulmonary embolus. In two patients the catheter slipped from its original position into the jugular vein and needed to be removed. One of these patients also developed a pneumothorax post-Hickman line insertion, requiring insertion of a chest drain.
The use of 5-FU as a single agent in NSCLC has shown little activity with response rates of less than 10% (Selawry, 1973; Kris et al., 1985) and there has seemed little rationale for its use in this disease when given as a bolus injection. There have been two previous reports of the use of 5-fluorouracil as a short infusion in combination with cisplatin and etoposide in advanced NSCLC, neither suggesting an advantage in terms of either response rate or survival compared with previous established cisplatin-based regimens (Flaherty et al., 1991; Lynch et al., 1993) . Continuous infusional 5-FU, however, has not previously been assessed as front-line therapy in this setting. Giving 5-FU as a continuous infusion allows increased dose intensity without a significant increase in toxicity, and recent results in colon cancer (Lokich et al., 1989) , gastric cancer (Findlay et al., 1994) and breast cancer (Smith et al., 1993) suggest increased activity with this approach. This study was designed to see if a similar approach in combination with other known active agents would lead to a regimen with improved efficacy in advanced NSCLC.
The response rate obtained with this regimen does suggest significant activity in this tumour type, however it appears no Ellis et al.. 1995) . As in these studies. the vast majority of patients attained symptomatic relief after two courses of chemotherapy, with only a small number achieving a response after further treatment. This reinforces our impression that, in general, palliative chemotherapy should be stopped after two cycles in patients who have not achieved significant symptomatic relief.
Although active in advanced non-small-cell lung cancer and offering useful symptomatic relief in a significant proportion of patients, the toxicity profile and complexity of MCF suggests little benefit over other previously reported regimens. We therefore feel that there is little to be gained by taking this regimen forward into large randomised studies.
